Profile data is unavailable for this security.
About the company
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
- Revenue in USD (TTM)1.00m
- Net income in USD-94.11m
- Incorporated2006
- Employees121.00
- LocationAdverum Biotechnologies Inc100 Cardinal WayREDWOOD CITY 94063United StatesUSA
- Phone+1 (650) 649-1004
- Fax+1 (650) 329-8151
- Websitehttps://adverum.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Repare Therapeutics Inc | 66.52m | -84.05m | 120.73m | 179.00 | -- | 0.6901 | -- | 1.81 | -2.00 | -2.00 | 1.56 | 4.12 | 0.270 | -- | 3.95 | 371,642.50 | -34.11 | -23.40 | -40.73 | -26.37 | -- | -- | -126.34 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Lineage Cell Therapeutics Inc | 8.72m | -20.11m | 121.12m | 75.00 | -- | 1.83 | -- | 13.89 | -0.1096 | -0.1096 | 0.0474 | 0.3505 | 0.086 | -- | 20.83 | 116,253.30 | -19.77 | -19.53 | -22.80 | -22.59 | 95.00 | 89.13 | -229.91 | -370.88 | -- | -- | 0.0021 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
| Ventyx Biosciences Inc | 0.00 | -152.52m | 121.62m | 75.00 | -- | 0.436 | -- | -- | -2.37 | -2.37 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -48.98 | -- | -52.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Context Therapeutics Inc | 0.00 | -30.15m | 122.25m | 5.00 | -- | 1.46 | -- | -- | -0.9117 | -0.9117 | 0.00 | 1.12 | 0.00 | -- | -- | 0.00 | -55.16 | -- | -58.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -82.60m | 124.68m | 66.00 | -- | 1.37 | -- | -- | -2.07 | -2.07 | 0.00 | 2.23 | 0.00 | -- | -- | 0.00 | -56.88 | -- | -66.15 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Outlook Therapeutics Inc | 0.00 | -94.05m | 124.90m | 24.00 | -- | -- | -- | -- | -8.12 | -8.12 | 0.00 | -3.57 | 0.00 | -- | -- | 0.00 | -205.48 | -214.69 | -- | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.89 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
| Coherus Biosciences Inc | 304.34m | -450.00k | 126.73m | 235.00 | -- | -- | 26.10 | 0.4164 | -0.0892 | -0.0892 | 2.60 | -0.7636 | 0.5591 | 2.94 | 1.58 | 994,575.20 | -0.0827 | -21.43 | -0.1626 | -29.32 | 44.71 | 79.01 | -0.1479 | -36.56 | 1.09 | -3.92 | 1.50 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Fennec Pharmaceuticals Inc | 49.35m | -1.13m | 127.29m | 36.00 | -- | -- | -- | 2.58 | -0.1004 | -0.1004 | 1.75 | -0.1886 | 1.27 | 2.22 | 5.66 | -- | -2.91 | -73.43 | -3.40 | -84.32 | 93.52 | -- | -2.30 | -383.28 | 7.64 | 0.5978 | 1.21 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| Candel Therapeutics Inc | 0.00 | -52.20m | 127.70m | 42.00 | -- | -- | -- | -- | -1.74 | -1.74 | 0.00 | -0.4749 | 0.00 | -- | -- | 0.00 | -145.85 | -- | -227.04 | -- | -- | -- | -- | -- | -- | -30.42 | -- | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Adverum Biotechnologies Inc | 1.00m | -94.11m | 128.35m | 121.00 | -- | 0.8906 | -- | 128.35 | -6.03 | -6.03 | 0.0585 | 6.93 | 0.0046 | -- | -- | 8,264.46 | -43.66 | -36.39 | -50.24 | -39.04 | -- | -- | -9,411.10 | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Cardiff Oncology Inc | 689.00k | -43.01m | 129.37m | 31.00 | -- | 2.50 | -- | 187.76 | -0.9493 | -0.9493 | 0.0152 | 1.01 | 0.0091 | -- | 1.69 | 22,225.81 | -56.80 | -31.24 | -66.22 | -33.56 | -- | -- | -6,238.17 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Skye Bioscience Inc | 0.00 | -21.24m | 129.85m | 11.00 | -- | 1.71 | -- | -- | -0.8405 | -0.8405 | 0.00 | 2.50 | 0.00 | -- | -- | 0.00 | -43.73 | -232.67 | -54.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Inhibikase Therapeutics Inc | 0.00 | -19.57m | 133.04m | 8.00 | -- | -- | -- | -- | -2.72 | -2.72 | 0.00 | -0.0711 | 0.00 | -- | -- | 0.00 | -175.81 | -66.49 | -267.87 | -85.55 | -- | -- | -- | -1,139.14 | -- | -- | -- | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to Adverum Biotechnologies Inc's reporting currency: US Dollar USD
41.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BML Capital Management LLCas of 30 Sep 2024 | 2.27m | 10.90% |
| Franklin Advisers, Inc.as of 30 Sep 2024 | 1.76m | 8.46% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 1.36m | 6.55% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.01m | 4.86% |
| Geode Capital Management LLCas of 30 Sep 2024 | 439.06k | 2.11% |
| Logos Global Management LPas of 30 Sep 2024 | 416.67k | 2.00% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Sep 2024 | 412.37k | 1.98% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 369.62k | 1.78% |
| Soleus Capital Management LP (Investment Management)as of 30 Sep 2024 | 287.25k | 1.38% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 234.71k | 1.13% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
